PF-06821497 Traitement du CPPC récidivant/réfractaire, du cancer de la prostate résistant à la castration et du lymphome folliculaire
UNE PHASE I D'ESCALADE DE DOSE ET UNE ÉTUDE DE COHORTE ÉLARGIE DU PF-06821497 DANS LE TRAITEMENT DE PATIENTS ADULTES ATTEINTS D'UN CANCER DU POUMON À PETITES CELLULES (SCLC) EN RECHUTE/RÉFRACTAIRE, D'UN CANCER DE LA PROSTATE RÉSISTANT À LA CASTRATION (CRPC) ET D'UN LYMPHOME FOLLICULAIRE (LF)
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Pfizer CT.gov Call Center
- Numéro de téléphone: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Lieux d'étude
-
-
-
Haskovo, Bulgarie, 6300
- Résilié
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510120
- Actif, ne recrute pas
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, Chine, 410013
- Actif, ne recrute pas
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210009
- Actif, ne recrute pas
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, Chine, 210008
- Actif, ne recrute pas
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, Chine, 325000
- Actif, ne recrute pas
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Corée du Sud, 13620
- Recrutement
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], Corée du Sud, 03080
- Actif, ne recrute pas
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Corée du Sud, 07985
- Actif, ne recrute pas
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Corée du Sud, 03722
- Actif, ne recrute pas
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, Corée du Sud, 35015
- Actif, ne recrute pas
- Chungnam national university hospital
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Hospital Universitari Vall d'Hebron
-
Barcelona, Espagne, 08036
- Recrutement
- Hospital Clinic de Barcelona
-
Barcelona, Espagne, 08023
- Recrutement
- Hospital Quironsalud Barcelona
-
Madrid, Espagne, 28034
- Recrutement
- Hospital Universitario Ramon y Cajal
-
Madrid, Espagne, 28050
- Recrutement
- Hospital Universitario HM Sanchinarro
-
Madrid, Espagne, 28040
- Recrutement
- H.U. Fundación Jiménez Díaz
-
Madrid, Espagne, 28041
- Recrutement
- Hospital Universitario 12 De Octubre
-
Málaga, Espagne, 29010
- Recrutement
- Hospital Universitario Virgen de la Victoria
-
Valencia, Espagne, 46026
- Actif, ne recrute pas
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, Espagne, 08908
- Actif, ne recrute pas
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, Espagne, 12002
- Actif, ne recrute pas
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Espagne, 28223
- Recrutement
- Hospital Quironsalud Madrid
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espagne, 28040
- Recrutement
- Hospital Clinico San Carlos
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japon, 277-8577
- Actif, ne recrute pas
- National Cancer Center Hospital East
-
-
-
-
-
Bydgoszcz, Pologne, 85-048
- Pas encore de recrutement
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, Pologne, 75-581
- Actif, ne recrute pas
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, Pologne, 30-348
- Recrutement
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, Pologne, 35-326
- Actif, ne recrute pas
- Centrum Medyczne MEDYK
-
Warsaw, Pologne, 02-781
- Actif, ne recrute pas
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
-
Moscow, Russie, 117186
- Actif, ne recrute pas
- LLC "Neyro-klinika"
-
Moscow, Russie, 125284
- Résilié
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, Russie, 129301
- Résilié
- SBHI of Moscow City Clinical Hospital
-
Omsk, Russie, 644013
- Résilié
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, Russie, 197341
- Résilié
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, Russie, 197758
- Résilié
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, Russie, 198255
- Résilié
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, Russie, 150054
- Résilié
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, Russie, 196603
- Actif, ne recrute pas
- Private Medical Institution "Euromedservice"
-
-
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85719
- Actif, ne recrute pas
- Banner-University Medical Center Tucson
-
Tucson, Arizona, États-Unis, 85719
- Actif, ne recrute pas
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, États-Unis, 85724
- Actif, ne recrute pas
- The University of Arizona Cancer Center
-
Tucson, Arizona, États-Unis, 85741
- Résilié
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, États-Unis, 92801
- Actif, ne recrute pas
- Pacific Cancer Medical Center INC
-
Duarte, California, États-Unis, 91010
- Actif, ne recrute pas
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, États-Unis, 91010
- Actif, ne recrute pas
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, États-Unis, 06856
- Actif, ne recrute pas
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, États-Unis, 66205
- Actif, ne recrute pas
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, États-Unis, 66205
- Actif, ne recrute pas
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, États-Unis, 66160
- Actif, ne recrute pas
- The University of Kansas Hospital
-
Kansas City, Kansas, États-Unis, 66160
- Actif, ne recrute pas
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, États-Unis, 66211
- Actif, ne recrute pas
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, États-Unis, 66205
- Actif, ne recrute pas
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40202
- Actif, ne recrute pas
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, États-Unis, 40202
- Actif, ne recrute pas
- Norton Hospital
-
Louisville, Kentucky, États-Unis, 40202
- Actif, ne recrute pas
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, États-Unis, 20850
- Résilié
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Actif, ne recrute pas
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, États-Unis, 02115
- Actif, ne recrute pas
- Brigham and Women's Hospital
-
Newton, Massachusetts, États-Unis, 02459
- Actif, ne recrute pas
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68130
- Recrutement
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Actif, ne recrute pas
- Hackensack University Medical Center
-
Hackensack, New Jersey, États-Unis, 07601
- Actif, ne recrute pas
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, États-Unis, 29572
- Recrutement
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, États-Unis, 29572
- Recrutement
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, États-Unis, 78705
- Résilié
- Texas Oncology - Austin Midtown
-
Dallas, Texas, États-Unis, 75390
- Actif, ne recrute pas
- UT Southwestern Medical Center
-
Dallas, Texas, États-Unis, 75390
- Actif, ne recrute pas
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, États-Unis, 75390
- Actif, ne recrute pas
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, États-Unis, 75390
- Actif, ne recrute pas
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, États-Unis, 75063
- Résilié
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, États-Unis, 75063
- Résilié
- US Oncology Investigational Products Center
-
Irving, Texas, États-Unis, 75039
- Recrutement
- NEXT Dallas
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Actif, ne recrute pas
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, États-Unis, 98362
- Actif, ne recrute pas
- Olympic Medical Center
-
Poulsbo, Washington, États-Unis, 98370
- Actif, ne recrute pas
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, États-Unis, 98195
- Actif, ne recrute pas
- University of Washington Medical Center
-
Seattle, Washington, États-Unis, 98109
- Actif, ne recrute pas
- Fred Hutchinson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
- Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
Autres noms:
|
|
Expérimental: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
Autres noms:
|
|
Expérimental: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
Autres noms:
|
|
Expérimental: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
Autres noms:
Oral continuous
Autres noms:
|
|
Expérimental: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
Autres noms:
Oral continuous
Autres noms:
|
|
Expérimental: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
Autres noms:
|
|
Expérimental: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
Autres noms:
|
|
Expérimental: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
Autres noms:
Oral continuous
Autres noms:
|
|
Expérimental: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Autres noms:
Oral continuous
Autres noms:
|
|
Expérimental: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Autres noms:
Oral continuous
Autres noms:
Oral solution
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Délai: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
Délai: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
Délai: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
Délai: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
Délai: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Délai: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Délai: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
Délai: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
Délai: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Délai: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Directeur d'études: Pfizer CT.gov Call Center, Pfizer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- sécurité
- pharmacocinétique
- étiquette ouverte
- efficacité
- CPRCm
- pharmacodynamique
- Floride
- rechuté
- réfractaire
- cancer du poumon à petites cellules
- escalade de dose
- SCLC
- lymphome folliculaire
- expansion de la dose
- EZH2
- cancer de la prostate résistant à la castration
- activateur de zeste homologue 2
- prostatecancer-study.com
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par site
- Tumeurs
- Attributs de la maladie
- Maladies du système immunitaire
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies pulmonaires
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome non hodgkinien
- Lymphome
- Carcinome bronchique
- Tumeurs bronchiques
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Récurrence
- Carcinome pulmonaire à petites cellules
- Lymphome folliculaire
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Azoles
- Triazoles
- Pipérazines
- Itraconazole
- enzalutamide
- PF06821497
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- C2321001
- 2023-509179-18-00 (Identificateur de registre: CTIS (EU))
- EZH2 (Autre identifiant: Alias Study Number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .